A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Stephen P Mulligan, Devinder Gill, Paul Turner, William E. P. Renwick, Maya Latimer, Naomi Mackinlay, Leanne Berkahn, David Simpson, Philip Campbell, Cecily J. Forsyth, Gavin Cull, Rosemary Harrup, Melanie Sulda, Giles Best, Mathias Bressel, Juliana Di Iulio, Bryone J Kuss

    Research output: Contribution to journalMeeting Abstractpeer-review

    Fingerprint

    Dive into the research topics of 'A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity'. Together they form a unique fingerprint.

    Medicine & Life Sciences